Medical News

RSS

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Mammographic density is one of the strongest predictors of breast cancer risk: Researchers

Women who have a breast density of 75 percent or higher on a mammogram have a risk of breast cancer that is four to five times greater than that of women with little or no density, making mammographic breast density one of the strongest biomarkers of breast cancer risk.

22 Apr 2010

Health record push lacks FDA oversight, risks safety problems

The Huffington Post Investigative Fund: "As federal officials encourage the rapid expansion of electronic medical records to help doctors improve care and cut costs, they lack a reliable and systematic method for tracking the safety of these products, agency data and audits show. Instead, the Food and Drug Administration depends on a spotty warning system that can take a year to flag serious computer malfunctions and other software glitches.

22 Apr 2010

Berwick may face difficult confirmation in Senate

News outlets continue to report on Donald Berwick, who was nominated by President Barack Obama to be administrator of the Centers for Medicare and Medicaid Services.

22 Apr 2010

Positive results from initial clinical trial of ClariVein catheter

Results from the initial clinical trial of the ClariVein® catheter, used in a new minimally invasive treatment for varicose veins, have been announced. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

22 Apr 2010

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

Researchers at Johns Hopkins say they have discovered the way in which red wine consumption may protect the brain from damage following a stroke.

22 Apr 2010

OPAL study: Fish oil supplements offer no benefits for cognitive function in older people

The largest ever trial of fish oil supplements has found no evidence that they offer benefits for cognitive function in older people.

22 Apr 2010

Simcere's diosmectite API in generic drug Biqi passes EU-GMP inspection

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its diosmectite, the Active Pharmaceutical Ingredient (API) in Simcere's branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the European Union countries.

22 Apr 2010

Online Wiki offers information, comfort and community for families facing autism transition

Among the many challenges families caring for individuals with autism spectrum disorders face, perhaps the most difficult of all arrive "when the school bus stops." When a child with autism ages out of systems and supports designed for those up to ages 18-21, families face the daunting challenge of finding new resources and creating new communities for their children. Unfortunately, finding necessary services and supports can be very difficult.

22 Apr 2010

State's Medicaid funds tapped for federal health overhaul

Kaiser Health News staff writer Christopher Weaver writes: "The new health care law could shift billions of dollars from cash-strapped states to the federal government by changing the way Medicaid prescription drug rebates are treated, according to state and industry officials and an examination of Medicaid spending data" (Weaver, 4/20).

22 Apr 2010

FDA approves Akorn's ANDA supplement for Erythromycin

Akorn, Inc. a niche generic pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g. The company intends to begin shipping the product immediately.

22 Apr 2010

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Celldex Therapeutics, Inc. today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, is the subject of a poster presentation at the 2010 American Association for Cancer Research 101st Annual Meeting in Washington DC.

22 Apr 2010

Abbott acquires Facet Biotech

Abbott has completed its acquisition of Facet Biotech Corporation, strengthening its pharmaceutical pipeline in immunology and oncology.

22 Apr 2010

Alaska is 20th state to join health reform lawsuit; Okla. and La. consider signing on

Alaska Republican Gov. Sean Parnell has said he will make Alaska the 20th state to join a lawsuit challenging the constitutionality of the new health reform law, The Anchorage Daily News/McClatchy report.

21 Apr 2010

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Broadening the scope of innovation for cardiovascular interventions beyond the heart, Medtronic, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Complete® SE Vascular Stent System to be used for the treatment of peripheral arterial disease (PAD) in the iliac arteries, major blood vessels within the pelvis that supply blood to the lower extremities.

21 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

HemaQuest Pharmaceuticals closes $12M Series B financing

HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing compounds to treat sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures. HemaQuest's investor syndicate includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

21 Apr 2010

ForeverGreen Worldwide reports 30.5% increase in gross profit margins for fourth-quarter 2009

ForeverGreen Worldwide Corp. today announced fourth quarter and its 2009 full year financial results.

21 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Medical News

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Mammographic density is one of the strongest predictors of breast cancer risk: Researchers

Health record push lacks FDA oversight, risks safety problems

Berwick may face difficult confirmation in Senate

Positive results from initial clinical trial of ClariVein catheter

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

OPAL study: Fish oil supplements offer no benefits for cognitive function in older people

Simcere's diosmectite API in generic drug Biqi passes EU-GMP inspection

Online Wiki offers information, comfort and community for families facing autism transition

State's Medicaid funds tapped for federal health overhaul

FDA approves Akorn's ANDA supplement for Erythromycin

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Abbott acquires Facet Biotech

Alaska is 20th state to join health reform lawsuit; Okla. and La. consider signing on

FDA approves Medtronic's Complete SE Vascular Stent System for PAD

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

HemaQuest Pharmaceuticals closes $12M Series B financing

ForeverGreen Worldwide reports 30.5% increase in gross profit margins for fourth-quarter 2009

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News